Eribulin mesylate
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Rhabdomyosarcoma
Conditions
Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
Trial Timeline
Apr 17, 2018 → Jan 21, 2022
NCT ID
NCT03441360About Eribulin mesylate
Eribulin mesylate is a phase 2 stage product being developed by Eisai for Relapsed/Refractory Rhabdomyosarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03441360. Target conditions include Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03441360 | Phase 2 | Completed |
| NCT03583944 | Approved | Completed |
| NCT03361436 | Phase 1 | Active |
| NCT03437083 | Pre-clinical | Completed |
| NCT03058406 | Pre-clinical | Completed |
| NCT02481050 | Phase 2 | Completed |
| NCT02338037 | Phase 1 | Completed |
| NCT02171260 | Phase 1 | Completed |
| NCT03245112 | Pre-clinical | UNKNOWN |
| NCT01961544 | Approved | Completed |
| NCT01458249 | Phase 2 | Completed |
| NCT01463891 | Pre-clinical | Completed |
| NCT01328249 | Phase 2 | Completed |
| NCT01240421 | Pre-clinical | Completed |
| NCT01268150 | Phase 2 | Completed |
| NCT01269346 | Phase 2 | Completed |
| NCT01142661 | Pre-clinical | Completed |
| NCT01106248 | Phase 1 | Completed |
| NCT00965523 | Phase 2 | Completed |
Competing Products
20 competing products in Relapsed/Refractory Rhabdomyosarcoma